Panacea Biotec Quarterly Results for Trading Insights
In Mar 2026, Panacea Biotec (PANACEABIO) reported revenue ₹172 Cr and net profit ₹-1 Cr — revenue +1.8% YoY. Also explore PANACEABIO share price history to track price trends across different timeframes.
PANACEABIO Quarterly Results — Revenue, Profit & EPS Highlights
Panacea Biotec latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Panacea Biotec share price chart.
- Revenue of ₹172 Cr in Mar 2026 (-16.9% vs Jun 2026, +1.8% vs Mar 2025)
- Net Profit of ₹-1 Cr in Mar 2026 (-150.0% vs Jun 2026, +50.0% vs Mar 2025)
- EBITDA of ₹8 Cr in Mar 2026 (-38.5% vs Jun 2026)
- Operating Margin of 2.0% in Mar 2026 (-1.0pp vs Jun 2026)
- Earnings Per Share of ₹0.08 in Mar 2026 (-78.9% vs Jun 2026)
Panacea Biotec Quarterly Results — Revenue, EBITDA, Net Profit & EPS
PANACEABIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 172 | 207 | 150 | 169 | 184 | -16.9% | 1.8% |
| Net Profit (₹ Cr) | -1 | 2 | -14 | -2 | 4 | - | - |
| EBITDA (₹ Cr) | 8 | 13 | -9 | 9 | 16 | - | - |
| EPS (₹) | 0.08 | 0.38 | -2.27 | -0.31 | 0.66 | - | - |
| Operating Margin (%) | 2.0% | 3.0% | -13.0% | -20.0% | -1.0% | - | - |
PANACEABIO Share Price Trend — 1-Year Movement Across Quarterly Results
Panacea Biotec 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse PANACEABIO financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
PANACEABIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Panacea Biotec latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1900.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 168.1 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8560.0 | 2,986 | 751 | -5.0% | - | 25.2% | 302.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 5013.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 435.5 |
|
Cipla
Mar 2026 |
₹114,875.60 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1104.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 87.3 |
All amounts in ₹ Crores